Previous efforts to provide a drug therapy for obstructive sleep apnea patients have fallen short of the finish line but Apnimedsays it is getting closer to taking its daily, oral combination pill into pivotal Phase III trials after a pair of successful Phase II data readouts for AD109.
On 13 October, the Cambridge, MA-based company reported that AD109 – which combines the novel, selective antimuscarinic agent aroxybutynin with the selective norepinephrine reuptake inhibitor atomoxetine – met multiple endpoints in the APC-003 study in moderate-to-severe sleep apnea and in the APC-004 trial in mild-to-moderate disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?